155 related articles for article (PubMed ID: 36797602)
1. The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years.
Balma M; Liberini V; Buschiazzo A; Racca M; Rizzo A; Nicolotti DG; Laudicella R; Quartuccio N; Longo M; Perlo G; Terreno E; Abgral R; William Huellner M; Papaleo A; Deandreis D
Curr Med Imaging; 2023; 19(8):817-831. PubMed ID: 36797602
[TBL] [Abstract][Full Text] [Related]
2. Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.
Balma M; Liberini V; Racca M; Laudicella R; Bauckneht M; Buschiazzo A; Nicolotti DG; Peano S; Bianchi A; Albano G; Quartuccio N; Abgral R; Morbelli SD; D'Alessandria C; Terreno E; Huellner MW; Papaleo A; Deandreis D
Front Med (Lausanne); 2022; 9():881551. PubMed ID: 35492341
[TBL] [Abstract][Full Text] [Related]
3. Gastrin-releasing peptide receptor as a theranostic target in breast cancer: a systematic scoping review.
Baun C; Naghavi-Behzad M; Hildebrandt MG; Gerke O; Thisgaard H
Semin Nucl Med; 2024 Mar; 54(2):256-269. PubMed ID: 38342656
[TBL] [Abstract][Full Text] [Related]
4. Theragnostic radionuclides: a clinical perspective.
Koziorowski J; Ballinger J
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):306-314. PubMed ID: 34881851
[TBL] [Abstract][Full Text] [Related]
5. The value of tumor markers in men with metastatic prostate cancer undergoing [
Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H
Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967
[TBL] [Abstract][Full Text] [Related]
6. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
9. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
10. Nuclear Medicine and Cancer Theragnostics: Basic Concepts.
Zoi V; Giannakopoulou M; Alexiou GA; Bouziotis P; Thalasselis S; Tzakos AG; Fotopoulos A; Papadopoulos AN; Kyritsis AP; Sioka C
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835806
[TBL] [Abstract][Full Text] [Related]
11. PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?
Rizzo A; Dall'Armellina S; Pizzuto DA; Perotti G; Zagaria L; Lanni V; Treglia G; Racca M; Annunziata S
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011032
[TBL] [Abstract][Full Text] [Related]
12. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Harris PE; Zhernosekov K
Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
[TBL] [Abstract][Full Text] [Related]
13. Advances in Radioligand Theranostics in Oncology.
Lawal IO; Abubakar SO; Ndlovu H; Mokoala KMG; More SS; Sathekge MM
Mol Diagn Ther; 2024 May; 28(3):265-289. PubMed ID: 38555542
[TBL] [Abstract][Full Text] [Related]
14. PSMA theragnostics for metastatic castration resistant prostate cancer.
Song H; Guja KE; Iagaru A
Transl Oncol; 2022 Aug; 22():101438. PubMed ID: 35659674
[TBL] [Abstract][Full Text] [Related]
15. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
17. Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT.
Werner RA; Thackeray JT; Pomper MG; Bengel FM; Gorin MA; Derlin T; Rowe SP
J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31331016
[TBL] [Abstract][Full Text] [Related]
18. GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals.
Kurth J; Potratz M; Heuschkel M; Krause BJ; Schwarzenböck SM
Nuklearmedizin; 2022 Jun; 61(3):247-261. PubMed ID: 35668669
[TBL] [Abstract][Full Text] [Related]
19. Theragnostics in prostate cancer.
Farolfi A; Mei R; Ali S; Castellucci P
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):333-341. PubMed ID: 35133097
[TBL] [Abstract][Full Text] [Related]
20. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
